Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 28-12-2015
AUM:
₹ 1,325.19 Cr
Expense Ratio
2.21%
Benchmark
NIFTY Pharma TRI
ISIN
INF277K016A9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Rajat Srivastava
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | 5.14 | 21.75 | 13.21 |
| Nifty Pharma TRI | 13.97 | 24.12 | 12.21 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
31.0755
Last change
0.08 (0.2565%)
Fund Size (AUM)
₹ 1,325.19 Cr
Performance
11.43% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund Manager
Rajat Srivastava
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.87 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 5.92 |
| HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 5.45 |
| ABBOTT INDIA LIMITED EQ | 5.37 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.17 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 5.07 |
| RAINBOW CHILDRENS MEDICARE LIMITED EQ | 4.23 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.06 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 3.73 |
| Dr. Reddys Laboratories Ltd | 3.73 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 93.74 |
| Chemicals | 5.19 |
| Financial Services | 0.67 |
Peer Comparison
| Scheme Name | 5Y (%) |
|---|---|
| Tata India Pharma & Healthcare Reg Gr | 13.21 |